In this April 9, 2020 file photo, a chemist displays hydroxychloroquine tablets in New Delhi, India. U.S. regulators are revoking emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19. The Food and Drug Administration said Monday, June 15 that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. (AP Photo/Manish Swarup, File)
By Matthew Perrone
The U.S. Food and Drug Administration is revoking its emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.
The agency said Monday that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.
The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure, and muscle or nerve damage.
The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.
On Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except in formal studies.
Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took the drug preemptively against infection.
Georgie Dickins, founder of Women in Leadership Global and author of ‘Leading with Impact,’ shares thoughts on women in business and how to cultivate a supportive community.
Gregory Daco, chief economist at EY and Jordan Shapiro, senior managing director at Bachrach Group, break down February’s jobs report and what it means for workers.
Linda Moore, president and CEO of Technet, explains why the U.S. should be a leader in A.I., plus why deepfakes and misinformation could be a concern during the election season.
Steve Preston, president and CEO of Goodwill Industries International, shares how the organization’s programs have helped over 2 million people develop their tech skills.
Box office analyst Shawn Robbins breaks down how the theater business is faring as two of 2023’s biggest movies are on their way to the Academy Awards.
Burns McKinney, portfolio manager at NFJ Investment Group, discusses how the Fed is balancing recession risks and interest rate cuts, plus whether the tech rally will broaden.
Nick Wolny, CNet editor, tells consumers about BNPL being added to credit reports – and why they may want to be more cautious about using it as an option.
